BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunctio

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 7.1 million shares of its common stock and warrants to purchase up to approximately 3.55 million shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, was sold for a purchase price of $2.1025, a premium to the closing bid price on Friday June 18, 2010, as reported by the NASDAQ Stock Market.

The warrants to purchase additional shares are exercisable at an exercise price of $2.45 per share beginning on June 23, 2010 and will expire on June 22, 2015. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be primarily used to fund BioSante’s LibiGel Phase III clinical study program and for general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ: RODM), acted as the exclusive placement agent for the transaction. JMP Securities LLC, Oppenheimer & Co. Inc. and Trout Capital LLC acted as financial advisors.

All of the securities were offered and sold pursuant to an effective shelf registration statement filed by BioSante with the Securities and Exchange Commission. This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of common stock or warrants of BioSante. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.

Forward-Looking Statements

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



CONTACT:

For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316; [email protected]
or
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; [email protected]

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.